Cofrogliptin

PreclinicalSmall molecule

Haisco Pharmaceutical Group Co., Ltd.

Cofrogliptin is one of 24 small molecule programs targeting Type 2 Diabetes. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 DiabetesActive, not recruiting

Type 2 DiabetesPreclinical

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

NOVOLIN R

Novo Nordisk

Preclinical

5 2

Glargine

Eli Lilly

Preclinical

8 3

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 4

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 5

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 6

Lovaza

AstraZeneca

Preclinical

1 7

Sulfonylureas

Eli Lilly

Preclinical

1 8

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 9

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

1 10

Blank Control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

N/ANot yet recruiting

Type 2 Diabetes

NCT07122102

Q4 2027

N/ANot yet recruiting

Beta-Cell Function

NCT07460336

Clinical

Trials by Indication[1]

Type 2 Diabetes1 trial

A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes

Not yet recruiting· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·N/A·NCT07122102·200 enrolled

Beta-cell Function1 trial

Effects of Cofrogliptin on Beta-Cell Function in LADA Patients

Not yet recruiting·SSecond Xiangya Hospital of Central South University·N/A·NCT07460336·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cofrogliptin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cofrogliptin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cofrogliptin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Haisco Pharmaceutical Group Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Haisco Pharmaceutical Group Co., Ltd.

Cofrogliptin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Trials by Indication[1]

Type 2 Diabetes1 trial

Beta-cell Function1 trial

References

Drug Info

Quick Facts

Related News